We're all set for a new experience. To visit the old Ventura website, click here.
Ventura Wealth Clients Login here
Refer and earnSupport
logosearch
Create Account
hamburger
home
breadcrumbStocks
breadcrumbSyngene International Ltd Share Price

NSEBSE
NSEBSE
noteThere is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
1D
1W
1M
1Y
3Y
5Y
Max
Open-
High-
Low-
Prev. Close-
Avg. Traded Price-
Volume-

MARKET DEPTH

info2
Total bid0.00
Total ask0.00
OrdersQtyBid
AskQtyOrders

HIGH/LOW

info2
1d
1w
1m
3m
52w

LOW/HIGH

₹624.35a day ago
₹636.00a day ago
arrow

LOWER/UPPER CIRCUITS

₹564.55
₹689.95
arrow
Syngene International Ltd Stock performance
arrow

KEY OBSERVATIONS

info
positive
negative
neutral
noteAnnual Revenue,rose 3.77%, in the last year to ₹3,714.2 Cr. Its sector's average revenue growth for the last fiscal year was 10.81%.
noteQuarterly Revenue,rose 11.03% YoY to ₹1,036.9 Cr. Its sector's average revenue growth YoY for the quarter was 11.45%.
noteInterest Coverage Ratio,is 20.97, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).
View more

LONG-TERM PRICE ANALYSIS

info
Stock return5Y CAGR : 18.74%
Net profit growth 5Y CAGR : 8.99%

Similar stocks

Syngene International Limited, incorporated in 1993, is an internationally reputed contract research and manufacturing organization, which supports R&D programs from lead generation to clinical supplies. The company’s multi-disciplinary skills in integrated drug discovery and development include capabilities in medicinal chemistry, biology, in vivo pharmacology, toxicology, custom synthesis, process R&D, cGMP manufacturing, formulation and analytical development along with Clinical development services. The company has state-of-the-art research facilities certified with ISO 9001:2008, ISO 14001:2004, and OHSAS 18001:2007. The company’s animal facilities are GLP certified by the Indian authorities and AAALAC accredited.
personal

Grow your wealth with more research recommendations

+91